New to the $TELO story? Learn about TeloView® technology in 90 seconds ⬇️

https://t.co/LzF21OvPdU

TeloView assays have been validated as binary risk classifiers to provide an actionable test result that supports the decision making of oncologists. Telo Genomics’ lead assay, TeloViewSMM, fills a critical unmet need by risk stratifying smoldering myeloma patients.

2024 was a significant year for expanding the evidence of TeloView utility. Telo Genomics completed the clinical validation of its first assay, TeloViewSMM for smoldering multiple myeloma, with a publication in American Journal of Hematology.

https://t.co/dmL2Jo2zK1

Global News is celebrating the work of Sabine Mai, founder and interim CEO of Telo Genomics. “A Manitoba professor has made leaps and bounds in cancer research, developing a tool (TeloView) that could tack years onto patients' lives.” ➡️ https://t.co/t617OIu2iF

Myeloma Canada’s 15th Scientific Roundtable had the absolute highest quality of talks in myeloma immunotherapy, featuring Vincent Rajkumar, Annette Hay, Nizar Bahlis, Tom Martin. Telo Genomics’ CTO spoke about TeloView prognostics product offering for multiple myeloma.

Telo Genomics has participated in the 21st International Myeloma Society Annual Meeting in Rio De Janeiro. We thank all the hematologists, academics and industry for their engagement at our poster session and booth. #IMS24

Telo Genomics is validating 2 MRD applications in an active clinical trial, each with their own value propositions. The two MRD assays join the suite of Telo Genomics product offerings supporting #myeloma hematologists along the entire disease spectrum.

Telo Genomics’ New Generation MRD combines a superior cancer cell detection sensitivity with single cell 3D-Telomere Analysis. The prognostic assessment of this assay is based on the genomic instability in the #MRD cells instead of their count. Our MRD: https://t.co/mtNq3nZSLw

Most MRD assays don’t directly assess residual cancer cells, but rather infer their count through amplification of markers like ctDNA. Telo Genomics’ first MRD offering, TeloMRD-D, targets cancer cells directly. For more on our MRD, check out: https://t.co/mtNq3nZSLw

Telo Genomics is at the 21st International Myeloma Society meeting. Visit our booth 1133# and meet the team.

Meet the Telo Genomics team in Rio De Janeiro during the 21st International Myeloma Society exhibits or visit our poster session.

Telo Genomics was featured by Leede Financial Inc. in their Healthcare & Biotechnology weekly review of August 23.

Telo Genomics is proud to share that the validation of TeloView’s utility as a predictor of outcomes in #Hodgkin Lymphoma (cHL) has been published in Cancers. A predictive model showed strong accuracy of (0.83), sensitivity (0.82) and specificity (0.78). https://t.co/uwhd6QarST

Telo Genomics’ recent CLIA certification announcement was featured by GenomeWeb and the article reached the top 5 most popular of the week. https://t.co/ANUjIsnbJD

Telo Genomics’ landmark publication in the American Journal of Hematology is being covered and celebrated by University of Manitoba, where Telo’s core technology was first developed. https://t.co/nbzNzMKjMp

Telo Genomics would like to acknowledge the remarkable team effort over the last 2 years in expanding laboratory capabilities while matching international standards. #CAP #CLIA #ISO15189

Telo Genomics is constantly focused on innovation to expand its IP portfolio. Our leading offerings are covered by patents spanning up to year 2043, as well as trademarked features and proprietary software tools.

TeloViewSMM is a reliable independent biomarker for predicting progression of smoldering #myeloma. The risk assessment supersedes other scoring systems currently in the clinic; presenting an opportunity for combined use and potential synergy. https://t.co/UyYXDnYiHn

Telo Genomics is participating in the 21st International Myeloma Society meeting. Our abstract will contribute to the poster session and the abstract discussion session.